

III. Amendments to the Claims

To more clearly distinguish the claims over the combination of the Katsarava and Aoki references, applicants have amended the claims to limit the scope of the claims to treating an acute pain medication overuse disorder "caused by overuse of acute pain medication." Support for such claim amendments can be found at at least page 8, lines 4-7 and page 9, lines 1-6 of the specification.

The combination of Katsarava and Aoki does not teach or suggest a method of treating pain medication overuse disorder caused by overuse of acute pain medication by administering botulinum toxin to a patient thereby treating the pain medication overuse disorder.

The claims as amended do not introduce any new matter and are patentable over Aoki et al, therefore, withdrawal of the rejection is requested.

IV. New claims 21-28

New Claim 21-28 have been added.

Support for claim 21 can be found at at least page 1, lines 11-14; page 27, lines 17-20; page 29, lines 11-13; and page 32, lines 4-20 of the specification.

Support for claims 22-24 can be found at at least page 29, lines 11-19 and page 29, line 32 through page 30, line 5 and original claims 2-4 of the specification.

Support for claim 25 can be found at at least page 27, lines 26-29 and original claim 5 of the specification.

Support for claim 26 can be found at at least page 34, lines 5-7 and original claim 6 of the specification.

Support for claim 27 can be found at at least original claim 7 of the specification.

Support for claim 28 can be found as stated above.

Thus, no new matter is added by and no new issues are raised by the addition of claims 21-28 to the application.